More

    Apple Faces Patent Challenge in the US

    Apple takes a sales pause for Series 9 and Ultra 2 smartwatches in the US, responding to a patent dispute involving blood oxygen tech. Explore the details and possible outcomes.

    Apple will stop selling smartwatches due to a patent conflict.

    In order to resolve a patent issue about the technology underlying the blood oxygen feature on the devices, Apple announced on Monday that it would be pausing sales of its Series 9 and Ultra 2 smartwatches in the United States starting this week.

    The action follows an October order from the U.S. International Trade Commission (ITC), which found that Apple Watches violate the patent rights of medical technology company Masimo and potentially prevent Apple from importing the devices.

    President Joe Biden is reviewing the verdict through December 25. In the event that the ruling is upheld, Apple has stated that it will take the appropriate action. According to the Biden administration’s Office of the U.S. Trade Representative, Ambassador Katherine Tai is carefully considering all factors in this case. Dec. 26 is when the prohibition would take effect if it is not vetoed.

    The watch’s sales will be suspended, according to the firm, from its website beginning on December 21 and from Apple retail stores following December 24. The disagreement has no bearing on other versions that do not have the blood oxygen sensor, such as Apple’s less expensive Apple Watch SE model.

    Stay Updated about the latest technological developments and reviews by following TechTalk, and connect with us on Twitter, Facebook, Google News, and Instagram. For our newest video content, subscribe to our YouTube channel.

    Read More: iOS 17.2.1 Unleashed: Apple’s Stealth Bug Extermination

    iOS 17.2.1 update

    Latest articles

    spot_imgspot_img

    Related articles

    Leave a reply

    Please enter your comment!
    Please enter your name here

    spot_imgspot_img